<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407186</url>
  </required_header>
  <id_info>
    <org_study_id>CRITICS</org_study_id>
    <nct_id>NCT00407186</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)</brief_title>
  <official_title>A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combined chemotherapy and
      radiotherapy (in comparison to chemotherapy alone) as adjuvant treatment after surgery for
      gastric cancer. Prior to surgery all patients will receive neo-adjuvant chemotherapy as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mainstay of curative treatment of gastric cancer is radical surgical dissection. Because
      most patients in the Western world present with advanced stages long term survival is found
      in about 25%, with local recurrences as part of treatment failure in up to 80% of cases.
      Studies examining the role of more extended lymph node dissections (D1 vs. D2), adjuvant
      radiotherapy or adjuvant chemotherapy did not result in a clinical relevant improvement of
      survival. In 2001 results of a South West Oncology group (SWOG) trial that randomized between
      surgery and surgery with chemoradiotherapy were published. This trial, that was hampered by
      suboptimal surgery (less than D1 in majority of patients) and radiotherapy (2D radiotherapy;
      35% protocol deviations) showed an absolute increase in median survival of 9 months. More
      recently results of the MAGIC study, which randomized between surgery and surgery plus 6
      perioperative courses of ECF chemotherapy, were presented. This regimen resulted in an
      absolute 5-year survival benefit of 13% and in a 10% higher resectability rate.

      This phase III prospectively randomized study investigates whether chemoradiotherapy (45 Gy
      in 5 weeks with daily cisplatin and capecitabine) after preoperative chemotherapy (3x ECC
      (epirubicin, cisplatin, capecitabine)) and adequate (D1+) surgery leads to improved survival
      in comparison with postoperative chemotherapy (3x ECC). Furthermore, toxicity of both
      treatment regimens will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2007</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">788</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 adjuvant courses epirubicin, cisplatin, capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin+capecitabine</intervention_name>
    <description>cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.</description>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>45 Gy in 25 fracions (5 days/week)</description>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin+cisplatin+capecitabine</intervention_name>
    <description>3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)</description>
    <arm_group_label>2chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ib-IVa (no distant metastases) gastric cancer (histologically proven); tumor bulk in
             the stomach

          -  WHO &lt; 2

          -  Age â‰¥18 yrs

          -  Operable gastric cancer

          -  No prior abdominal radiotherapy or chemotherapy

          -  Tumornegative laparoscopy when CT suggests peritoneal carcinomatosis

          -  Start treatment within 10 working days after registration

          -  Written informed consent

        Exclusion Criteria:

          -  T1N0 disease (endoscopic ultrasound)

          -  Distant metastases

          -  Inoperable patients; due to technical surgery-related factors or general condition

          -  Previous malignancy, except adequately treated non-melanoma skin cancer or in-situ
             cancer of the cervix uteri.

          -  Solitary functioning kidney that will be within the radiation field

          -  Major surgery within 4 weeks prior to study treatment start, or lack of complete
             recovery from the effects of major surgery

          -  Uncontrolled (bacterial) infections

          -  Significant cardiac disorders

          -  Continuous use of immunosuppressive agents

          -  Concurrent use of the antiviral agent sorivudine or chemically related analogues

          -  Hearing loss &gt; CTC grade 1

          -  Neurotoxicity &gt; CTC grade 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel Verheij, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nederlands Kanker Insituut/Antoni van Leeuwenhoek Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Dutch Colorectal Cancer Group</description>
  </link>
  <link>
    <url>http://www.nki.nl</url>
    <description>Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital)</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRITICS</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>adjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>capecitabine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>epirubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

